Literature DB >> 22573035

Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels : anti-Müllerian hormone in poor responders in assisted reproductive treatment.

Handan Celik1, Devran Bıldırcın, Davut Güven, Mehmet B Cetinkaya, Tayfun Alper, A Sertaç Batuoğlu.   

Abstract

OBJECTIVE: To evaluate the predictive value of random serum anti-Müllerian hormone (AMH) in the assessment of ovarian response in patients with diminished ovarian reserve (DOR; diagnosed after the observation of elevated baseline levels of early follicular follicle-stimulating hormone [FSH]) who were undergoing intracytoplasmic sperm injection-embryo transfer (ICSI-ET) and to compare the random serum AMH and baseline FSH levels in these patients for the prediction of poor ovarian response.
DESIGN: Retrospective study.
SETTING: University hospital. PATIENTS: One hundred and thirty-nine patients who were undergoing ICSI-ET cycles with early follicular FSH level >9 IU/mL. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Poor ovarian response in ICSI-ET cycles.
RESULTS: For the identification of women at risk of cycle cancellation, an AMH cut-off level ≤1.2 ng/mL had 97.3 % sensitivity, 31.3 % specificity, 33.9 % positive predictive value, and 96.9 % negative predictive value in the women with high baseline FSH levels. An AMH cut-off level ≥1 ng/mL had a sensitivity of 58.7 % and specificity of 95.1 % for prediction of retrieval of 4 or more oocytes. By using a serum AMH cutoff level of 1.5 ng/mL, the ongoing pregnancies were predicted with 83.3 % sensitivity and 82.5 % specificity and yielded a positive predictive value of 31.2 % and a negative predictive value 98.1 %.
CONCLUSION: Measurement of random serum AMH level is a useful tool in the prediction of ovarian response in patients with high serum early follicular FSH levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573035      PMCID: PMC3430775          DOI: 10.1007/s10815-012-9794-y

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  21 in total

Review 1.  A rational approach to the management of low responders in in-vitro fertilization.

Authors:  V Karande; N Gleicher
Journal:  Hum Reprod       Date:  1999-07       Impact factor: 6.918

2.  Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome.

Authors:  F Raga; F Bonilla-Musoles; E M Casañ; F Bonilla
Journal:  Hum Reprod       Date:  1999-06       Impact factor: 6.918

Review 3.  Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr.

Authors:  Murat Arslan; Silvina Bocca; Sebastián Mirkin; Gerardo Barroso; Laurel Stadtmauer; Sergio Oehninger
Journal:  Fertil Steril       Date:  2005-09       Impact factor: 7.329

4.  Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve.

Authors:  László F J M M Bancsi; Frank J M Broekmans; Marinus J C Eijkemans; Frank H de Jong; J Dik F Habbema; Egbert R te Velde
Journal:  Fertil Steril       Date:  2002-02       Impact factor: 7.329

5.  ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria.

Authors:  A P Ferraretti; A La Marca; B C J M Fauser; B Tarlatzis; G Nargund; L Gianaroli
Journal:  Hum Reprod       Date:  2011-04-19       Impact factor: 6.918

Review 6.  Prognostic assessment of ovarian reserve.

Authors:  R T Scott; G E Hofmann
Journal:  Fertil Steril       Date:  1995-01       Impact factor: 7.329

7.  Anti-Müllerian hormone and its role in ovarian function.

Authors:  Maria J G Gruijters; Jenny A Visser; Alexandra L L Durlinger; Axel P N Themmen
Journal:  Mol Cell Endocrinol       Date:  2003-12-15       Impact factor: 4.102

8.  Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.

Authors:  M M Lee; P K Donahoe; T Hasegawa; B Silverman; G B Crist; S Best; Y Hasegawa; R A Noto; D Schoenfeld; D T MacLaughlin
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

9.  Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981.

Authors:  J E Garcia; G S Jones; A A Acosta; G Wright
Journal:  Fertil Steril       Date:  1983-02       Impact factor: 7.329

10.  High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome.

Authors:  J A Land; M I Yarmolinskaya; J C Dumoulin; J L Evers
Journal:  Fertil Steril       Date:  1996-05       Impact factor: 7.329

View more
  3 in total

1.  Serum antimüllerian hormone measurements with second generation assay at two distinct menstrual cycle phases for prediction of cycle cancellation, pregnancy and live birth after in vitro fertilization.

Authors:  Carolina P Rezende; Ana L Rocha; Cynthia Dela Cruz; Lavinia E Borges; Helen L Del Puerto; Fernando M Reis
Journal:  J Assist Reprod Genet       Date:  2014-07-12       Impact factor: 3.412

2.  Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.

Authors:  Zaher Merhi; Athena Zapantis; Dara S Berger; Sangita K Jindal
Journal:  J Assist Reprod Genet       Date:  2013-08-21       Impact factor: 3.412

3.  An Individualized Recommendation for Controlled Ovary Stimulation Protocol in Women Who Received the GnRH Agonist Long-Acting Protocol or the GnRH Antagonist Protocol: A Retrospective Cohort Study.

Authors:  Ming-Xing Chen; Xiang-Qian Meng; Zhao-Hui Zhong; Xiao-Jun Tang; Tian Li; Qian Feng; Enoch Appiah Adu-Gyamfi; Yan Jia; Xing-Yu Lv; Li-Hong Geng; Lin Zhu; Wei He; Qi Wan; Yu-Bin Ding
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.